Connect with us

Hi, what are you looking for?

Tuesday, Sep 26, 2023
Mugglehead Magazine
Alternative investment news based in Vancouver, B.C.


Curaleaf buys 55% of licensed German pot producer Four 20 Pharma

Curaleaf to acquire complete control of Four 20 Pharma within two years of the commencement of adult use in Germany.

Curaleaf expands its leadership team, adds to members to board of directors
Image via Curaleaf

Curaleaf Holdings, Inc. (CSE: CURA) (OTCQX: CURLF) continues to expand its presence in the European Union after buying 55 per cent of a licensed cannabis producer in Germany.

On Tuesday, the Massachusetts cannabis producer announced the acquisition deal via its subsidiary Curaleaf International Holdings Limited. The partnership creates a strategic pathway for Curaleaf to acquire complete control of Four 20 Pharma within two years of the commencement of adult use in Germany. Four 20 Pharma is among the largest German pot operators with a market share of over 10 per cent.

According to the company, Germany is one of the largest medical cannabis markets in Europe with an “addressable” market of over €200 million in 2022 and expected to grow to nearly €1 billion by the end of 2024 via adult-use legalization, which is slated to begin in late 2023 or early 2024.

“By partnering with Four20 Pharma, Curaleaf’s European business will immediately gain additional critical mass and be in a superior position to capitalize on the accelerating trends in the European cannabis market,” CEO Boris Jordan said in a statement.

Read more: Curaleaf launches new health and wellness brand

Read more: Curaleaf launches limited-edition craft cannabis product series

“Four 20 Pharma is a leading German distributor with a branded product that consumers love,” Curaleaf president Miles Worne said.

“They’ve captured significant market share in Germany by sourcing product from top EU-GMP certified suppliers around the world and building strong connections with German medical consumers by providing the highest quality flower in a namesake branded offering.”

“As such, Four 20 Pharma is uniquely positioned to capitalize on Germany’s conversion from a medical to an adult use market and we’re thrilled to be partnering with their talented management team,” he explained.


Follow Mugglehead on Twitter

Like Mugglehead on Facebook

Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

You May Also Like


Lucy expects to complete the acquisition within 90 days


Newcrest runs the Lihir gold project in PNG and has a 50/50 JV with Harmony Gold at the country's Wafi-Golpu copper-gold mine


The newly acquired property spans 67.7 square kilometres and Aya has obtained a total of 7 permits

AI and Autonomy

MosaicML is known for its state-of-the-art large language AI models that are significantly cheaper to train than others used previously